Divyanshoo Kohli, MD
Gastroenterology · Spokane, WANPI 1649569393
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,090 of the $3,118 with a category attached, or 99.1%. Olympus America Inc. accounts for 99.1% of it on its own, with 1 other manufacturer making up the rest.
Across 5 payments — averaging $623.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$3K
- AbbVie$28
Across 8 payments — averaging $16,918 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Fujifilm Healthcare Americas Corporation$106K
- Olympus Corporation Of The Americas$30K
What the payments were for
- Speaking & faculty fees$3,09099%
- Food & beverage$281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 4 | $3,090 |
| AbbVie | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,118 in reported general payments places this provider in the 75th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 12 | $77,753 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 64 | $1,175 |
| Mesalamine | 14 | $1,095 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 46 | $788 |
| Omeprazole | 65 | $751 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 31 | $570 |
| Pantoprazole Sodium | 63 | $431 |
| Famotidine | 14 | $261 |
| Ondansetron Hcl | 12 | $91 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Spokane
- Eashen LiuSpokane$62K
- Harold PreiksaitisSpokane$50K
- Michael KestellSpokane$22K
- Miguel Ordonez CastellanosSpokane$16K
- Nicolas Villa GuillenSpokane$15K
- Michael ChioreanIssaquah$1.4M
- Kris KowdleySeattle$1.4M
- Venkatachala MohanBellevue$564K
- Scott LeeSeattle$220K
- John SunTacoma$219K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.